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Objectives The goal of this work was to evaluate the accuracy of a new heart failure (HF) sensor (HFS) (Heart Failure Sen-
sor, CardioMEMS Inc., Atlanta, Georgia) pulmonary artery pressure (PAP) monitoring compared with Swan-Ganz
(SG) (Hospira, Inc., Lake Forest, Illinois) catheterization and echocardiography (ECHO) in ambulatory HF patients.
Background There is an increasing interest in the development of ambulatory monitoring devices aiming to adjust therapy
and prevent hospitalizations in HF patients.
Methods Twelve patients with HF and New York Heart Association functional class II to IV were included in this study. The
HFS was deployed into the pulmonary artery under angiography, allowing wireless PAP measurement. Two inde-
pendent blind operators performed 3 HFS measurements at each visit, with simultaneous ECHO at 2, 14, 30,
60, and 90 days. Swan-Ganz catheterization was performed at 0 and 60 days. Linear regression was used as a
measure of agreement. Variability between methods and interobserver variability were evaluated by Bland-
Altman analysis.
Results Mean age was 63  14.6 years. Systolic PAP was 64  22 mm Hg and 58  22 mm Hg for HFS and SG, re-
spectively (p  0.01). Both methods showed a significant correlation (r2  0.96 baseline, r2  0.90 follow-up,
p  0.01), with a mean difference of 6.2  4.5 mm Hg. Diastolic PAP was 23  14 mm Hg and 28  16 mm
Hg for HFS and SG, respectively (r2  0.88 baseline, r2  0.48 follow-up, p  0.01), with a mean difference of
1.6  6.8 mm Hg. Systolic PAP was 60  20 mm Hg and 62  12 mm Hg for HFS and ECHO, respectively (r2 
0.75, p  0.01), with a mean difference of2.6  11 mm Hg. There was no significant interobserver difference.
Conclusions The HFS provides an accurate method for PAP assessment in the intermediate follow-up of HF patients.
(J Am Coll Cardiol 2007;50:2375–82) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.061p
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(ongestive heart failure (HF) is a chronic, degenerative
ondition that impairs the heart’s ability to pump blood at
ormal filling pressures to adequately meet the metabolic
equirements of the body. Nearly 4.9 million Americans
uffer from various degrees of HF, with about 400,000 new
ases identified each year. Heart failure is the leading cause
f hospital admissions in U.S. patients older than 65 years
1). One in 5 HF patients die within 1 year of diagnosis, and
nly 15% survive more than 10 years (2). The disease is also
ostly, due in large part to the frequency of acute decom-
rom the *Pontificia Universidad Cato´lica de Chile, Santiago, Chile; †Hospital
IPRECA, Santiago de Chile, Santiago, Chile; and the ‡University of Alabama at
irmingham, Birmingham, Alabama.c
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ccepted June 3, 2007.ensation episodes, which require emergency treatment and
ospitalization.
See page 2383
In nonrandomized studies, acute therapy with vasodila-
ors and diuretics to reduce filling pressures has been
ssociated with improved symptoms and reduction of the
egree of mitral regurgitation (3–9). For inpatient HF
atients whose signs and symptoms of congestion do not
esolve with initial therapy, it appears reasonable to consider
nvasive hemodynamic monitoring in experienced sites
10,11).
In the outpatient setting, serial laboratory testing and
areful clinical follow-up lack the required sensitivity to
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compensation risk (12) and often
cannot avoid repeated hospital-
izations. The currently available
methods for routine hemodynamic
evaluation (Swan-Ganz [SG]
[Hospira, Inc., Lake Forest, Illi-
nois] catheterization and echocar-
diography [ECHO]) are costly
and not suitable for repeated mea-
sures in the ambulatory setting. A
considerable amount of investi-
gation has been directed to de-
velop alternative methods for
central hemodynamic evaluation
in order to adjust therapy in am-
bulatory patients with severe
symptoms despite optimal med-
ical therapy guided only by clin-
cal assessment. Implantable hemodynamic sensors may
nable frequent monitoring of hemodynamic changes in HF
atients and could be used in tailoring vasodilator or diuretic
rug dosages (12,13) aiming to prevent hospital admission
or acute decompensation of the HF patient (14–16). This
s the first study to assess the accuracy of the radiofrequency-
ased wireless pressure heart failure sensor (HFS) for
easurements of pulmonary artery pressure (PAP) in pa-
ients with HF compared with the standard Swan-Ganz
SG) and ECHO methods.
ethods
atients. Twelve HF patients in New York Heart Associ-
tion (NYHA) functional class III to IV referred to a
ertiary center for acute decompensation, with normal ven-
ilation/perfusion lung scan and tricuspid regurgitation sig-
al at ECHO, which allowed for proper PAP determina-
ion, were included. All patients already on oral warfarin
efore the randomization were advised to continue their
edication and did not require additional antiplatelet ther-
py. Informed consent was obtained from all patients.
xclusion criteria were recent acute coronary syndrome,
oronary artery bypass surgery, or percutaneous coronary
ngioplasty within the last 3 months; mechanical right heart
alves; pulmonary or tricuspid stenosis, documented pulmo-
ary embolism, or pulmonary infarction within the last 3
onths; pregnant women; and active uncontrolled infec-
ion. The study protocol was approved by the ethics com-
ittees of the participating centers.
FS delivery system and implantation. The Cardio-
EMS Heart Failure Sensor (CardioMEMS Inc., Atlanta,
eorgia) (Fig. 1) consists of a 3-dimensional coil and a
ressure-sensitive capacitor encased within a hermetically
ealed, fused silica capsule completely covered in medical-
rade silicone. Two wired nitinol loops avoid sensor distal
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
ECHO  echocardiography
HF  heart failure
HFS  heart failure sensor
NYHA  New York Heart
Association
PAdia  diastolic
pulmonary artery pressure
PAP  pulmonary artery
pressure
PAsys  systolic
pulmonary artery pressure
RAP  right atrial pressure
SG  Swan-Ganzigration. The device is 15-mm long and 3-mm wide and is supplied pre-loaded, attached to a tether wire within a
elivery catheter.
Implantation was performed under fluoroscopy. A 7-F
edge catheter (Arrow International Inc., Reading, Penn-
ylvania) was advanced into the deployment site in the
ulmonary artery. Then, a 0.025-inch guidewire was ad-
anced through the catheter into the target site; the wedge
atheter was retired, and a 12-F sheath was advanced over
he guidewire, allowing the introduction of the HFS deliv-
ry catheter. Once the target site was reached, the tether
ire was pulled to release the sensor. A selective angiogra-
hy showing the correct position of the device and blood
ow distal to it was performed (Fig. 2).
FS PAP measurement. The coil and capacitor housed
ithin the HFS form a miniature electrical circuit that
esonates at a specific frequency. Pressure applied to the
ensor causes deflections on the pressure-sensitive surface
nd results in a characteristic shift in the resonant frequency.
he coil allows for electromagnetic coupling to the sensor
y an external antenna, which is held against the patient’s
ide or back in the approximate area of deployment of the
ensor. The antenna provides power to the device, contin-
ously measures its resonant frequency, and converts the
requency shifts in a real-time pressure waveform (17) (Fig.
). The system is calibrated for atmospheric pressure using
built-in sensor on the interrogating device. On the first
valuation, SG measurements were used as reference for
alibration. On each scheduled visit, PAP was noninvasively
etermined using the aforementioned method by 2 blinded
valuators. In order to accept a measurement as valid, signal
trength must be above 75%.
CHO evaluation of PAP. All patients underwent
CHO for evaluation of tricuspid regurgitation flow veloc-
15 mm 3 mm
Radiopaque
Markers
Figure 1 Heart Failure Sensor
The CardioMEMS Heart Failure Sensor consists of electronic components
housed within a hermetically sealed, fused silica capsule. Two wire loops of
nitinol prevent sensor distal migration.ty (VTR), which depends on the pressure gradient between
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December 18/25, 2007:2375–82 Radiofrequency-Based Wireless Sensor in HFhe right atria and right ventricle. Right atrial pressure
RAP) was estimated based on the respiratory motion of
he inferior vena cava (18). Systolic pulmonary artery
ressure (PAsys) was then calculated as:
PAsys 4VTR2RAP
ll determinations were made on an HP Agilent
ONOS 4500 (Agilent Technologies, Andover, Massa-
husetts) by a trained operator blinded for other
easurements.
atient evaluation and follow-up. Two independent
linded operators took 3 HFS measurements with a fixed
nterval of 5 min at each scheduled evaluation. Simulta-
eously with implantation, each patient underwent SG
atheterization. Follow-up schedule consisted in sensor and
cho-Doppler PAP measurements at 2, 14, 30, 60, and 90
ays. Also, SG measurements were repeated at day 60. All
A
B
Figure 2 Pulmonary Angiography During
Heart Failure Sensor Implantation
CardioMEMS Heart Failure Sensor in the left pulmonary artery (A).
A selective angiography shows unimpaired pulmonary artery blood flow (B).f the evaluations were done by blinded investigators.tatistical analysis. All values are expressed as mean 
D. Linear regression analysis was used for the comparison
f PAP obtained with HFS, SG, and ECHO at baseline
nd during the follow-up, and for the results of 2 indepen-
ent operators of the HFS device. Variability between the
ethods and interobserver variability was expressed relative
o the average PAP plus 2 SDs by Bland-Altman analysis;
or the former, PAP estimations of both operators were
veraged. The Student t test was performed to determine
he significance of the differences of the values obtained
ith different methods. A p value 0.05 was considered
tatistically significant.
esults
welve patients were incorporated into the study. Baseline
haracteristics are shown in Table 1. Implanting procedure
as feasible in all patients. Average implantation time was
1  31 min (range 19 to 110 min). The device was
eployed in the right pulmonary artery in 8 patients and in
he left pulmonary artery in the remaining 4. In 1 patient,
evice migration from right to left pulmonary artery was
bserved at day 2. Patients were discharged after 2.6  1.1
ays. During follow-up (median 62 days, range 11 to 189
ays) no adverse effects attributable to the procedure were
bserved.
omparison of PAP between HFS and SG. Systolic PAP
as 64  22 mm Hg and 58  22 mm Hg for HFS and
G, respectively (p  0.01). Linear regression and agree-
ent plots for PAsys from HFS and SG as a function of
verage measurement are shown in Figure 4. A significant
orrelation was observed for the PAsys measurement be-
ween HFS and SG (r2  0.90 at initial implant and r2 
.94 at follow-up, p  0.01), with a mean difference of
.2  4.5 mm Hg (Fig. 4). Likewise, diastolic pulmonary
Figure 3 Bedside 6-h Recordings
On top is the Swan-Ganz reading and at the bottom is the
CardioMEMS Heart Failure Sensor pulmonary artery pressure waveform.
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Radiofrequency-Based Wireless Sensor in HF December 18/25, 2007:2375–82rtery pressure (PAdia) was 23  14 mm Hg and 28  16
m Hg for HFS and SG, respectively (p  0.30). A good
orrelation was observed between HS and SG (r2  0.88 at
nitial implant, r2  0.48 at follow-up, p  0.01) with a
ean difference of 1.6  6.8 mm Hg (Fig. 5).
omparison of PAP between HFS and ECHO. Systolic
AP was 60  20 mm Hg and 62  12 mm Hg for HFS
nd ECHO, respectively (p  0.47). Linear regression
howed a good correlation between HS and ECHO mea-
urements (r2  0.75, p  0.01). The limits of agreement
nalysis for variability between both methods demonstrated
mean difference of 2.6  11 mm Hg, as shown in
igure 6. There was no significant variation over time in the
ifference between both methods. Echocardiography deter-
ination of PAdia was only feasible in 2 patients, showing
known limitation of the method and invalidating further
omparison.
nterobserver variability. The results of the interobserver
ariability assessment for PAsys are shown in Figure 7. No
ignificant difference was present between the 2 indepen-
ent observers. The limits of agreement analysis for inter-
bserver variability showed a mean difference of0.8 6.5
m Hg for PAsys. For PAdia, linear regression analysis
howed an adequate correlation (r2  0.79). The limits of
greement analysis demonstrated a mean difference of
2.5  5.7 mm Hg.
afety. There were no adverse effects associated with device
mplantation. All patients received intravenous unfractioned
eparin during the procedure and remained on oral warfarin
or an international normalized ratio between 2.0 to 3.0
fterward. Animal studies with long-term follow-up and
istopathological evaluation showed that the sensor is well
olerated by the local pulmonary artery wall and incorpo-
ated into the pulmonary artery tissue by stable fibrocellular
ncapsulation after 3 to 6 months of implantation. There
as no propensity for in-situ thrombus formation (unpub-
ished data, K. Robinson et al., 2005). As a precautionary
Baseline Characteristics
Table 1 Baseline Characteristics
Patient # Age (yrs) Gender Etiology
1 69 M Ischemic
2 70 M Ischemic
3 78 F Ischemic
4 56 M Valvular
5 46 M Valvular
6 59 M Idiopathic
7 29 M Idiopathic
8 60 M Ischemic
9 78 M Valvular
10 67 M Idiopathic
11 70 M Idiopathic
12 78 M Idiopathic
LVEF left ventricular ejection fraction; NYHA New York Heart Assoc
pressure; PAPS  systolic pulmonary artery pressure.easure, ventilation/perfusion scans were performed at mcreening and 14 days after implantation to further assess
he device’s security.
iscussion
he results demonstrate that this new HFS allows accurate
nd reliable noninvasive measurement of PAP in HF
atients, compared with the currently available methods
SG catheterization and ECHO). In porcine experimental
odels, the HFS had showed good correlation with invasive
ressure evaluations and no evidence of prothrombotic effect
n the pulmonary artery. Recently, our group published the
rst successful implant in an HF patient (19).
A number of studies had shown the limitations of careful
linical assessment of the hemodynamic profile in HF
atients (12,20) in order to identify patients at imminent
isk of decompensation. The role of B-type natriuretic
eptide (BNP) in this scenario requires further clarification.
mall clinical studies had suggested that BNP is a useful
ool for therapy tailoring in compensated HF patients
21,22); however, normal BNP values show a widespread
istribution. Moreover, 21% of symptomatic decompen-
ated patients could have BNP levels below the diagnostic
hreshold (22). Alternative strategies as routine hemody-
amic monitoring are a subject of controversy (13,23,24).
ovick et al. (25) were the first to report SG catheterization
s a tool for tailoring therapy in decompensated HF, with
romising initial results that were repeated in nonrandom-
zed clinical studies (26). The ESCAPE (Evaluation Study
f Congestive Heart Failure and Pulmonary Artery Cathe-
erization Effectiveness) trial (27) was the first randomized
linical trial aimed at evaluating the impact of invasive
emodynamic monitoring compared with standard care in
he in-hospital management of HF patients admitted for
ecompensation, with a history of repeated hospitalizations
nd systolic dysfunction (left ventricular ejection fraction
30%). Both groups showed significant clinical improve-
(%)
NYHA Functional
Class
Swan-Ganz Baseline PAP
PAPS/PAPD,
Mean (mm Hg)
IV 44/18, 28
III 52/27, 43
III 37/23, 29
III 69/37, 55
III 80/46, 60
III 72/41, 51
III 33/18, 25
III 38/24, 28
III 45/27, 31
III 53/32, 38
III 45/13, 36
III 61/20, 30
PAP pulmonary artery pressure; PAPD diastolic pulmonary arteryLVEF
25
25
24
25
30
24
25
20
22
19
30
31ent, without any difference in survival after discharge or
n
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December 18/25, 2007:2375–82 Radiofrequency-Based Wireless Sensor in HFew hospitalizations. There were, however, a significant
umber of complications associated with the catheteriza-
ion. These findings have been reproduced in 2 meta-
nalyses, evidencing the limitations of SG catheterization
or therapy tailoring and establishing the actual recommen-
ation to avoid routine use of invasive monitoring in
ecompensated HF (28–30).
Another strategy more suitable for outpatient monitoring
s repeated ECHO evaluation. The role of echocardiogra-
hy in the initial assessment of decompensated HF is
ndisputable and constitutes a current practice in most HF
linics. In the outpatient setting, ECHO allows identifica-
Figure 4 Comparison Between Heart Failure Sensor and Swan-G
Bland-Altman analysis (A) and linear correlation at implant (B) and at follow-up (C
artery pressure (PAsys) measurements. In panel A, data and the associated SD’s
2 follow-up intervals.ion of a group of patients with higher morbidity and tortality (31). In particular, presence of restrictive transmi-
ral flow patterns despite optimal management relates with
NP levels and PAP and is associated with a poorer
rognosis. However, repeated echocardiograms seem to add
ittle information to the initial prognostic assessment (32).
Implantable devices for ambulatory hemodynamic mon-
toring appeared the last few years as an alternative for
ptimizing clinical management of outpatient HF. Initial
bservational studies showed their usefulness in titrating
asodilation therapy in HF patients. The Chronicle device
Medtronic Inc., Minneapolis, Minnesota) is implanted
ubcutaneously in the pectoral region. A transvenous elec-
PAsys Determination
een Swan-Ganz and CardioMEMS Heart Failure Sensor (HFS) systolic pulmonary
ence intervals are combined for the readings taken at initial implant and for theanz
) betw
confidrode with an apical sensor located in the right ventricular
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Radiofrequency-Based Wireless Sensor in HF December 18/25, 2007:2375–82utflow track allows continuous monitoring of right ven-
ricular filling pressures. A first randomized trial with this
evice (33) enrolled HF patients in NYHA functional class
II to IV with standard therapy and repeated hospitaliza-
ions in the last 6 months. Right ventricular filling pressures
nd estimated PAPdia were transmitted to a central station,
ut they were not available to the clinicians for therapy
djustment in nearly 50% of the cases. In NYHA functional
lass III patients (85%), guided therapy resulted in a 24%
eduction in the number of hospitalizations due to decompen-
ated HF. In a similar trial, Yu et al. (34) evaluated an
Figure 5 Comparison Between Heart Failure Sensor and Swan-G
Bland-Altman analysis (A) and linear correlation at implant (B) and at follow-up (C
artery pressure (PAdia) measurements. In panel A, data and the associated SD’s
2 follow-up intervals.lternative method for central hemodynamic monitoring with ldevice capable of sensing transpulmonary impedance, which
losely correlates with intrapulmonary water content. Thirty-
hree patients underwent cardiac resynchronization therapy
ith an impedance-sensing device (OptiVol, Medtronic Inc.).
onsistently, decreases in transpulmonary impedance preceded
linical decompensation. Therapy with diuretics and vasodila-
ors raised impedance to normal levels, correlating inversely
ith pulmonary capillary wedge pressure.
Our study is the first clinical series of a new implantable
evice for real-time evaluation of PAP in HF patients.
lthough PAP changes have not shown a consistent corre-
PAdia Determination
een Swan-Ganz and CardioMEMS Heart Failure Sensor (HFS) diastolic pulmonary
nce intervals are combined for the readings taken at initial implant and for theanz
) betw
confideation with symptom improvement in the acute HF setting
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December 18/25, 2007:2375–82 Radiofrequency-Based Wireless Sensor in HF35), several trials demonstrate the value of PAP as a
redictor of morbidity and mortality in ambulatory patients
36,37). The lack of direct determination of right ventricular
ressures is a known limitation of pulmonary artery devices.
owever, there is no current data regarding which mea-
urement (PAP or right ventricular pressures) provides the
est guide in ambulatory HF patients. The potential of PAP
s a therapeutic guidance tool needs to be addressed in
urther studies. The main objective of this report was to
valuate the accuracy of HFS determinations compared
ith SG and ECHO, showing an excellent correlation with
oth new and traditional methods, high reproducibility of
he measurements, low interobserver variability, and a fa-
orable safety profile (33,38). Systolic pressure as deter-
ined with HFS tended to be higher than SG measure-
Figure 6 Comparison Between Heart Failure Sensor
and Echocardiographic PAsys Determination
Bland-Altman analysis (A) and linear correlation (B) between echocardiographic
and the CardioMEMS Heart Failure Sensor systolic pulmonary artery (PAsys)
measurements (HeartSure, CardioMEMS Inc.).ents. Because the systolic parameter is derived from theighest frequency part of the waveform, it is the most
ensitive parameter to differences in measurement method
nd sampling rate. The wireless sensor provides a direct
ressure measurement at the site, whereas the SG is an
ndirect measurement transmitted through a column of
uid. When measuring from the external transducer
hrough the column of fluid, there can be a higher level of
ariation as the frequency (rate of change) of the waveform
ncreases, due to whiplash, ringing, dampening, or other
rtifacts commonly seen in column of fluid measurements.
ore precise measurements of pulmonary systolic artery
ressure, as can be achieved with a Millar catheter (Millar
nstruments Inc., Houston, Texas), could provide a more
eliable standard for comparison. The simplicity of device
mplantation and the absence of a wire lead or the need of
attery replacement constitute another comparative advan-
age to other implantable devices currently available. Data
hown in this study are part of a larger phase II trial
esigned to evaluate the feasibility of device use in humans.
n most of the cases, PAP values were put at the disposition
f the clinical physician. An incremental use of diuretics and
asodilators and clinical subjective improvement were re-
orted in most patients (data not shown). However, study
esign and sample size do not allow evaluation of the impact
n clinical events.
onclusions
n summary, there is a growing interest in development of
ew devices to optimize management and clinical recogni-
ion of HF patients at imminent risk of decompensation.
he HF device has comparative advantages to other currently
vailable implantable devices in terms of simplicity of implan-
ation procedure, safety profile, and small size, providing
Figure 7 Interobserver Variability
Bland-Altman analysis for interobserver variability for the CardioMEMS
Heart Failure Sensor systolic pulmonary artery (PAsys) measurements.
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Radiofrequency-Based Wireless Sensor in HF December 18/25, 2007:2375–82ccurate measurements in the follow-up. In our opinion, these
ndings support the development of a randomized clinical
rial to evaluate the clinical usefulness of this device in
dvanced HF patients.
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